With regard to the adoption and use of digital health solutions in clinical R&D, where are we as an industry? In our latest Pharma15 Live! debate, BBK Worldwide founding principal Bonnie A. Brescia posed this question to the panel of industry experts. Justin Johnson, CEO of Biotaware, answered in no uncertain terms: “[the industry] is five to eight years behind where it should be.” Do you agree?
Topics: Pharma15
While it’s hard to believe that today is the last day on the DIA 2018 exhibition floor, we are excited to continue collaborating, presenting, and interacting with our industry colleagues. Our poster session “Real World Data Meets Real World Evidence in Patient Recruitment and Engagement” made way for productive conversation that embodies the spirit of the DIA Annual Meeting. Today, we are back with a new poster session titled “Taming the Study Data Explosion: How to Leverage KPIs to Maximize Performance.”
Topics: clinical research, clinical trials, DIA 2018, KPIs
With the first day on the DIA 2018 exhibition floor behind us, we are really looking forward to the next couple days of learning and collaborating with our industry colleagues. Today, we will be presenting compelling real world data and evidence from multiple clinical trials that focuses on easing the burden of patient participation.
Topics: Patient Recruitment, DIA 2018, Patient Experience
Over the past 35 years, BBK Worldwide has driven the development of patient recruitment and engagement through our products, services, experience, and thought leadership. With this in mind, we are pleased to announce our new marketplace position as The Patient Experience Company.
Topics: DIA 2018, Patient Experience
For those of us in the clinical R&D industry, this is among the most exciting (and busiest) times of the year. I’m talking, of course, about the Drug Information Association (DIA) Annual Meeting, June 24-28 in Boston.
With industry stakeholders gathering in our own backyard to exchange ideas in the pursuit of developing new therapies and accelerating efforts to enhance health and well-being, we could not be more thrilled. Ask anyone who has attended the DIA in the past, and they will tell you that it’s an occasion where a lot of exciting work gets done in a very short period of time.
Every year that we attend the DIA, we do our best to honor the spirit of the occasion and to acknowledge the importance of our industry colleagues working together in such a dynamic setting. This year, it is our goal to provide an experience that demonstrates our commitment to the patients who make clinical research possible.
Topics: DIA 2018, Patient Experience
The way people consume media is changing. With a projected 237.6 million estimated smartphone users by the end of 2018 in the United States alone (an increase of 13.3 million users from last year), the way people are accessing information is increasingly going mobile. Additionally, the Pew Research Center suggests that 64 percent of Americans between the ages 50 to 64 are using social media, preferring mediums like Facebook and YouTube. While the clinical trial industry is known to be slow in adopting newer technologies, the implications of these observed trends for patient recruitment speak for themselves. To get a closer look at the impact of digital media on clinical trial advertising, we spoke with our Director of Media and Research Sarah Mandracchia for her insights on some of the tactics and strategies that are shaping direct-to-consumer outreach in 2018.
Topics: advertising, clinical research, clinical trials, Digital Platforms
There are probably a good number of us in the clinical research and development industry that are spending a lot of time dotting the i’s and crossing the t’s on their Privacy Policies and otherwise ensuring that everything is ready for the 25th of May, the day that the EU’s General Data Protection Regulation (GDPR) goes into effect. And, there are probably a good number of us who have had a rather intense schedule over the past few months. But, I bet if you conducted a poll, you’d find that despite all the time-consuming work and activity, those of us concerned with the patient experience are greatly pleased that GDPR is finally here.
While sites should be held accountable for processing the referrals that are generated from clinical trial advertising, it is very important that these referrals are qualified so that sites are not wasting their time. Therefore, generating highly qualified referrals is the number one contributing factor to site engagement.
Do you agree? Disagree? Watch the latest clip from our first episode of Pharma15 Live! and leave a comment below.
Topics: Pharma15
There is a difference between “advertising” to generate referrals for clinical studies and “branding” for clinical trial sites. To remain relevant in a changing media landscape, sites must allocate part of their advertising budget to invest in branding. Do you agree? Disagree? Leave a comment below.
Topics: Pharma15
If regulatory bodies are reviewing advertising and content for digital channels, like social media, should they receive education to understand how these channels work?
Check out the latest clip from our first Pharma15 Live! debate. Do you agree? Disagree? Leave a comment below.
Topics: Social Media, clinical research, Pharma15